The short-acting CCBs were the only blood pressure drugs linked to higher pancreatic cancer risk, according to study lead author Zhensheng Wang.

However, people taking this class of drugs shouldn't panic, because their absolute risk of developing pancreatic cancer still remains very low. According to the U.S. National Cancer Institute, just 1.6 percent of Americans will develop the cancer during their lifetime. That means that -- even after accounting for a bump up in risk from taking a CCB -- an individual's odds for the disease remains minimal.

Still, the new finding was unexpected, said Wang, a postdoctoral associate at Baylor College of Medicine in Houston.

Prior investigations had hinted that CCBs might even protect against pancreatic cancer by boosting levels of a protein (sRAGE) known to keep inflammation in check, said Wang.

Reduced inflammation is typically associated with a lower risk for a range of cancers.

So what might explain the current results?

Wang noted that short-acting CCBs are "the least effective" blood pressure drug available. That could mean many of the women in the study had not achieved good blood pressure control to begin with, which could have boosted their risk for diabetes. And diabetes is a known risk factor for pancreatic cancer.

Wang also said blood samples taken from more than half the pancreatic cancer patients revealed that those who had ever taken a short-acting CCB also had notably lower levels of the sRAGE protein, compared with women who had taken other types of blood pressure drugs. That would mean less inflammation control and, therefore, potentially higher cancer risk.

Finally, he hypothesized that women who are prescribed short-acting CCBs might differ in some way from patients prescribed other types of blood pressure control.

In 1996, the U.S. Food and Drug Administration took steps to discourage doctors from prescribing short-acting nifedipine. It warned that some researchers had linked the drug to an increased risk for heart attack and stroke.

The current study followed more than 145,000 participants in the Women's Health Initiative study. They were between 50 and 79 years old at the start of the study, and medication use -- but not dosage -- was monitored between 1993 and 1998.

By 2014, more than 800 had developed pancreatic cancer, with risk up only among those who had been prescribed a short-acting CCB, Wang's team found.

For those who'd used the drugs three years or more, risk of pancreatic cancer was 107 percent higher than for those who took other blood pressure drugs.

Rutson also said if pancreatic cancer runs in your family, you might want to consult a doctor.

"If you have a familial history of pancreatic cancer, it is important to visit with a gastroenterologist, especially if you begin to exhibit any symptoms that are new or out of the ordinary," Rutson added.

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Wang said it typically strikes older adults with chronic medical conditions, such as high blood pressure.